Differential Regulation of 5-HT1A Receptor-G Protein Interactions in Brain Following Chronic Antidepressant Administration Julie G

Total Page:16

File Type:pdf, Size:1020Kb

Differential Regulation of 5-HT1A Receptor-G Protein Interactions in Brain Following Chronic Antidepressant Administration Julie G Differential Regulation of 5-HT1A Receptor-G Protein Interactions in Brain Following Chronic Antidepressant Administration Julie G. Hensler, Ph.D. Changes in 5-HT1A receptor function or sensitivity the dorsal and median raphe following chronic SSRI following chronic antidepressant treatment may involve treatment appears to be due to a reduced capacity of the changes in receptor-G protein interaction. We have 5-HT1A receptor to activate G protein. By contrast, no examined the effect of chronic administration of the SSRI significant change in postsynaptic 5-HT1A receptor- fluoxetine or the tricyclic antidepressant amitriptyline on stimulated [35S]GTP␥S binding was observed in any of the 35 ␥ 5-HT1A receptor-stimulated [ S]GTP S binding in forebrain areas examined following chronic antidepressant serotonergic cell body areas, and cortical and limbic treatment. Thus, changes in postsynaptic 5-HT1A receptor- structures using quantitative autoradiography. Treatment mediated responses reported to follow chronic SSRI or of rats with fluoxetine, but not amitriptyline, resulted in an tricyclic antidepressant administration most likely occur 35 ␥ attenuation of 5-HT1A receptor-stimulated [ S]GTP S distal to receptor-G protein interaction, perhaps at the level binding in the dorsal and median raphe nuclei. The binding of effector, or involving changes in neuronal function at the 3 of the antagonist radioligand [ H]MPPF to 5-HT1A receptor system or circuit level. sites was not altered, suggesting that the observed changes [Neuropsychopharmacology 26:565–573, 2002] 35 ␥ in 5-HT1A receptor-stimulated [ S]GTP S binding were © 2002 American College of Neuropsychopharmacology. not due to changes in receptor number. Thus, the Published by Elsevier Science Inc. desensitization of somatodendritic 5-HT1A autoreceptors in 35 KEY WORDS: [ S]GTPgammaS; Quantitative in particular has been implicated in affective disorders autoradiography; 5-HT1A receptor; 8-OH-DPAT; such as anxiety and depression. Adaptive changes in Fluoxetine; Amitriptyline; [3H]MPPF the serotonergic system are believed to underlie the Of the multiple types of receptors for serotonin (5-hydroxy- therapeutic effectiveness of the azapirone anxiolytics and a variety of antidepressant drugs. Thus, studies of tryptamine; 5-HT) present in brain, the 5-HT1A receptor the regulation of 5-HT1A receptor function may have important implications for our understanding the role of this receptor in the mechanism of action of these From the Department of Pharmacology, University of Texas therapeutic agents. Health Science Center-San Antonio, San Antonio, Texas. Chronic administration of selective serotonin re- Address correspondence to: J.G. Hensler, Ph.D. Department of uptake inhibitors (SSRIs) results in the desensitization Pharmacology, MC 7764, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, Tel.: (210) 567- of 5-HT1A somatodendritic autoreceptor function in the 4236, Fax: (210) 567-4303, E-mail: [email protected] dorsal raphe (see Blier and de Montigny 1994; Kreiss Received July 25, 2001; revised October 11, 2001; accepted Octo- and Lucki 1995; Le Poul et al. 2000). Chronic SSRI treat- ber 17, 2001. Online publication: 10/18/01 at www.acnp.org/citations/ ment also results in the desensitization of physiological Npp101801188. responses mediated by postsynaptic 5-HT1A receptors NEUROPSYCHOPHARMACOLOGY 2002–VOL. 26, NO. 5 © 2002 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/02/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(01)00395-5 566 J.G. Hensler NEUROPSYCHOPHARMACOLOGY 2002–VOL. 26, NO. 5 (Goodwin et al. 1987; Hensler et al. 1991; Li et al. 1996). phy to study the regulation of 5-HT1A receptor-G pro- Electrophysiological and neurochemical studies indi- tein interaction in brain following repeated antidepres- cate, however, that in hippocampus the sensitivity of sant administration. postsynaptic 5-HT1A receptor-mediated responses is not changed (Blier and de Montigny 1983; Chaput et al. 1986; Varrault et al. 1991; Le Poul et al. 2000). METHODS Unlike the SSRIs, chronic administration of tricyclic Animals antidepressants does not result in the desensitization of the 5-HT1A somatodendritic autoreceptor (Blier and de Male Sprague-Dawley rats (250–300 g; Harlan, India- Montigny 1980; Kreiss and Lucki 1995). Although some napolis, IN) were group-housed and maintained on a investigators have reported an attenuation of behav- 14:10 h day:night cycle with constant access to food and ioral and physiological responses mediated by postsyn- water. These studies were carried out in accordance aptic 5-HT1A receptors (Goodwin et al. 1987; Lesch et al. with the Guide for the Care and Use of Laboratory Animals 1990), this has not been a consistent observation (Lucki as adopted and promulgated by the National Institutes and Frazer 1982; Wozniak et al. 1987; Hensler et al. of Health. 1991; Gartside et al. 1992). Electrophysiological studies indicate that chronic treatment with tricyclic antide- Drug Treatment pressants results in the sensitization of postsynaptic neu- rons in hippocampus to 5-HT1A receptor agonists (de Rats were injected intraperitoneally (i.p.) with saline Montigny and Aghajanian 1978; Chaput et al. 1991). (n ϭ 12), fluoxetine (10 mg/kg) (n ϭ 8), or amitriptyline These discrepant observations regarding the regula- (10 mg/kg) (n ϭ 8) once a day for 14 days. Amitrip- ␷ ϭ ␷ ϭ tion of postsynaptic 5-HT1A receptor sensitivity follow- tyline ( 1 ml/kg) and fluoxetine ( 2 ml/kg) were ing chronic SSRI or tricyclic antidepressant administra- dissolved in water and injected according to body tion may be due to the effects of these drug treatments weight. These doses of amitriptyline and fluoxetine on complex neuronal circuits, or differences in the regu- were chosen from the literature to correspond to clini- lation of 5-HT1A receptor function in specific brain re- cally relevant doses (de Montigny and Aghajanian gions. In general, changes in 5-HT1A receptor number 1978; Czachura and Rasmussen 2000). Fresh fluoxetine have not been observed following chronic administra- and amitriptyline solutions were made each day. Ani- tion of antidepressants (Wieland et al. 1993; Hensler et mals were injected at the same time each day, specifi- al. 1991; Le Poul et al. 2000; Hervàs et al. 2001). Because cally between 11:00 A.M. and 1:00 P.M. Animals were changes in the sensitivity of 5-HT1A receptor-mediated sacrificed 48 h after the last injection. responses do not appear to be mediated by changes in 5-HT receptor binding, the basis for changes in 5-HT 1A 1A Tissue Preparation receptor function or sensitivity may involve changes in the capacity of the 5-HT1A receptor to activate G pro- Rat brains were rapidly removed and frozen on pow- tein. Receptor-stimulated [35S]GTP␥S binding is a direct dered dry ice. Brains were stored at –80ЊC until section- assay of receptor activation of G proteins, as it mea- ing. Coronal sections of 20 ␮m thickness were cut at sures the exchange of GDP for [35S]GTP␥S. [35S]GTP␥S Ϫ17ЊC in a cryostat microtome at the level of the lateral autoradiography allows the demonstration of receptor-G septum, dorsal hippocampus or dorsal raphe according protein interaction with neuroanatomical resolution. We to the atlas of the rat brain of Paxinos and Watson have used this approach previously to examine regional (1986). Sections were thaw-mounted onto gelatin- Њ differences in the regulation of the 5-HT1A receptor coated glass slides, desiccated at 4 C for 18 h under vac- at the level of receptor-G protein interaction following uum and then stored at Ϫ80ЊC until use. chronic agonist administration (Hensler and Durgam 2001). [35S]GTP␥S Autoradiography In the current study we have examined the effect of repeated administration of the SSRI fluoxetine or the Autoradiography of (Ϯ)8-OH-DPAT-stimulated [35S]GTP␥S tricyclic antidepressant amitriptyline on 5-HT1A recep- binding in brain sections was performed as previously tor-stimulated [35S]GTP␥S binding. Using quantitative described (Hensler and Durgam 2001). Because both autoradiography, this analysis was performed for post- MgCl2 and GDP affect the interaction of the agonist with 35 ␥ synaptic 5-HT1A receptors in forebrain areas, which the receptor and G protein, as well as basal [ S]GTP S serve as terminal field areas of serotonergic innerva- binding, we have determined in preliminary experi- tion, and presynaptic 5-HT1A receptors located on the ments the optimal concentrations of MgCl2 and GDP to soma and dendrites of serotonergic cell bodies in the maximize agonist-stimulated [35S]GTP␥S binding. The dorsal and median raphe nuclei. The present study is largest increases in 8-OH-DPAT-stimulated [35S]GTP␥S the first to report the use of [35S]GTP␥S autoradiogra- binding above basal were obtained with 2 mM GDP NEUROPSYCHOPHARMACOLOGY 2002–VOL. 26, NO. 5 Regulation of 5-HT1A Receptor-G Protein Interactions 567 35 ␥ and 3 mM MgCl2 in the assay buffer. Slide-mounted OH-DPAT-stimulated [ S]GTP S binding were quanti- sections were thawed and desiccated at 4ЊC for 2 h, and fied by the use of simultaneously exposed [14C] stan- then equilibrated in HEPES buffer (50 mM, pH 7.4), dards (ARC-146, American Radiochemicals, St. Louis, supplemented with 3 mM MgCl2, 0.2 mM EGTA, 100 MO). Standard curves were fit to pixel data obtained mM NaCl, and 0.2 mM dithiothreitol for 10 min at 30ЊC. from [14C] standards and tissue equivalent values (nCi/g) Sections were pre-incubated in HEPES buffer contain- provided by American Radiochemicals, and were used ing GDP (2 mM) for 10 min at 30ЊC, and then incubated to transform the actual regional densitometric values in HEPES buffer containing GDP (2 mM) and 80 pM into relative radioactivity measures. Nonspecific bind- [35S]GTP␥S, either in the absence or in the presence of ing of [35S]GTP␥S was subtracted from basal binding (Ϯ)8-OH-DPAT (1 ␮M), for 45 min at 30ЊC.
Recommended publications
  • Serotonin's Role in Alcohol's Effects on the Brain
    NEUROTRANSMITTER REVIEW IMPERATO, A., AND DI CHIARA, G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. Journal SEROTONIN’S ROLE IN ALCOHOL’S of Pharmacology and Experimental Therapeutics 239:219–228, 1986. EFFECTS ON THE BRAIN KITAI, S.T., AND SURMEIER, D.J. Cholinergic and dopaminergic modula- tion of potassium conductances in neostriatal neurons. Advances in David M. Lovinger, Ph.D. Neurology 60:40–52, 1993. LE MOINE, C.; NORMAND, E.; GUITTENY, A.F.; FOUQUE, B.; TEOULE, R.; AND BLOCH, B. Dopamine receptor gene expression by enkephalin Serotonin is an important brain chemical that acts as a neurons in rat forebrain. Proceedings of the National Academy of Sciences neurotransmitter to communicate information among USA 87:230–234, 1990. nerve cells. Serotonin’s actions have been linked to al- LE MOINE, C.; NORMAND, E.; AND BLOCH, B. Phenotypical character- cohol’s effects on the brain and to alcohol abuse. ization of the rat striatal neurons expressing the D1 dopamine receptor Alcoholics and experimental animals that consume gene. Proceedings of the National Academy of Sciences USA 88: large quantities of alcohol show evidence of differences 4205–4209, 1991. in brain serotonin levels compared with nonalcoholics. LYNESS, W.H., AND SMITH F.L. Influence of dopaminergic and sero- Both short- and long-term alcohol exposure also affect tonergic neurons on intravenous ethanol self-administration in the rat. the serotonin receptors that convert the chemical sig- Pharmacology and Biochemistry of Behavior 42:187–192, 1992. nal produced by serotonin into functional changes in the signal-receiving cell.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • The Serotonergic System in Migraine Andrea Rigamonti Domenico D’Amico Licia Grazzi Susanna Usai Gennaro Bussone
    J Headache Pain (2001) 2:S43–S46 © Springer-Verlag 2001 MIGRAINE AND PATHOPHYSIOLOGY Massimo Leone The serotonergic system in migraine Andrea Rigamonti Domenico D’Amico Licia Grazzi Susanna Usai Gennaro Bussone Abstract Serotonin (5-HT) and induce migraine attacks. Moreover serotonin receptors play an impor- different pharmacological preventive tant role in migraine pathophysiolo- therapies (pizotifen, cyproheptadine gy. Changes in platelet 5-HT content and methysergide) are antagonist of are not casually related, but they the same receptor class. On the other may reflect similar changes at a neu- side the activation of 5-HT1B-1D ronal level. Seven different classes receptors (triptans and ergotamines) of serotoninergic receptors are induce a vasocostriction, a block of known, nevertheless only 5-HT2B-2C neurogenic inflammation and pain M. Leone • A. Rigamonti • D. D’Amico and 5HT1B-1D are related to migraine transmission. L. Grazzi • S. Usai • G. Bussone (౧) syndrome. Pharmacological evi- C. Besta National Neurological Institute, Via Celoria 11, I-20133 Milan, Italy dences suggest that migraine is due Key words Serotonin • Migraine • e-mail: [email protected] to an hypersensitivity of 5-HT2B-2C Triptans • m-Chlorophenylpiperazine • Tel.: +39-02-2394264 receptors. m-Chlorophenylpiperazine Pathogenesis Fax: +39-02-70638067 (mCPP), a 5-HT2B-2C agonist, may The 5-HT receptor family is distinguished from all other 5- Introduction 1 HT receptors by the absence of introns in the genes; in addi- tion all are inhibitors of adenylate cyclase [1]. Serotonin (5-HT) and serotonin receptors play an important The 5-HT1A receptor has a high selective affinity for 8- role in migraine pathophysiology.
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • 52Nd Annual Meeting
    ACNP 52nd Annual Meeting Final Program December 8-12, 2013 The Westin Diplomat Resort & Spa Hollywood, Florida President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D. This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology. Dear ACNP Members and Guests, It is a distinct pleasure to welcome you to the 2014 meeting of the American College of Neuropsychopharmacology! This 52nd annual meeting will again provide opportunities for the exercise of the College’s core values: the spirit of Collegiality, promoting in each other the best in science, training and service; participation in Community, pursuing together the goals of understanding the neurobiology of brain diseases and eliminating their burden on individuals and our society; and engaging in Celebration, taking the time to recognize and enjoy the contributions and accomplishments of our members and guests. Under the excellent leadership of Randy Blakely and Pat Levitt, the Program Committee has done a superb job in assembling an outstanding slate of scientific presentations. Based on membership feedback, the meeting schedule has been designed with the goals of achieving an optimal mix of topics and types of sessions, increasing the diversity of participating scientists and creating more time for informal interactions. The presentations will highlight both the breadth of the investigative interests of ACNP membership
    [Show full text]
  • MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity
    The Journal of Neuroscience, August 1988, 8(8): 2788-2803 Methylenedioxyamphetamine (MDA) and Methylenedioxymetham- phetamine (MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: lmmunocytochemical Evidence for Neurotoxicity E. O’Hearn,” G. Battaglia, lab E. B. De Souza,’ M. J. Kuhar,’ and M. E. Molliver Departments of Neuroscience, and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ‘Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224 The psychotropic amphetamine derivatives 3,4-methylene- The synthetic amphetamine derivatives 3,4-methylenedioxy- dioxyamphetamine (MDA) and 3,4-methylenedioxymetham- amphetamine (MDA) and 3,4-methylenedioxymethamphet- phetamine (MDMA) have been used for recreational and amine (MDMA) are potent mood-altering drugs that have at- therapeutic purposes in man. In rats, these drugs cause large tained public interest (Seymour, 1986) due to their widespread, reductions in brain levels of serotonin (5HT). This study self-administration by young adults (e.g., Klein, 1985). These employs immunocytochemistry to characterize the neuro- drugs have also been proposed for medical use in psychotherapy toxic effects of these compounds upon monoaminergic neu- because they produce augmentation of mood and enhanced in- rons in the rat brain. Two weeks after systemic administra- sight (Naranjo et al., 1967; Yensen et al., 1976; Di Leo, 198 1; tion of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), Greer and Tolbert, 1986; Grinspoon and Bakalar, 1986). How- there is profound loss of serotonergic (5HT) axons through- ever, concern has been raised about the safety of these com- out the forebrain; catecholamine axons are completely pounds based on evidence that they may be toxic to brain seroto- spared.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Original Article E€Ects of Serotonin 1A Agonist on Acute Spinal Cord Injury
    Spinal Cord (2002) 40, 519 ± 523 ã 2002 International Spinal Cord Society All rights reserved 1362 ± 4393/02 $25.00 www.nature.com/sc Original Article Eects of serotonin 1A agonist on acute spinal cord injury Y Saruhashi*,1, Y Matsusue1 and S Hukuda2 1Department of Orthopedic Surgery, Shiga University of Medical Science, Otsu, Japan; 2Tane-daini Hospital, Osaka, Japan Study design: We evaluated the eects of serotonin (5-HT) agonists on in vitro models of spinal cord compressive injury. Evoked potentials in injured rat spinal cords (n=24) were recorded during perfusion with 5-HT agonists. Objectives: To evaluate the therapeutic eects of 5-HT agonists on the recovery of compound action potentials in injured spinal cords. Methods: Rat dorsal columns were isolated, placed in a chamber, and injured by extradural compression with a clip. Conducting action potentials were activated by supramaximal constant current electrical stimuli and recorded during perfusion with 5-HT agonists and antagonists. Results: After inducing compression injuries, mean action potential amplitudes were reduced to 33.9+5.4% of the pre-injury level. After 120 min of perfusion with Ringer's solution, the mean amplitudes recovered to 62.8+8.4% of the pre-injury level. At a concentration of 100 mM, perfusion with tandospirone (a 5-HT1A agonist) resulted in a signi®cantly greater recovery of mean action potential amplitudes at 2 h after the injury (86.2+6.9% of pre-injury value) as compared with the control Ringer's solution (62.8+8.4% of pre-injury value, P50.05). In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+11.7% of pre-injury value).
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • 5-HT1A Receptor-Dependent Modulation of Emotional
    www.nature.com/scientificreports OPEN 5-HT1A receptor-dependent modulation of emotional and neurogenic defcits elicited by Received: 8 May 2017 Accepted: 19 January 2018 prolonged consumption of alcohol Published: xx xx xxxx Arnauld Belmer 1,2, Omkar L. Patkar1,2, Vanessa Lanoue3 & Selena E. Bartlett 1,2 Repeated episodes of binge-like alcohol consumption produce anxiety, depression and various deleterious efects including alterations in neurogenesis. While the involvement of the serotonin receptor 1 A (5-HT1A) in the regulation of anxiety-like behavior and neurogenesis is well documented, its contribution to alcohol withdrawal-induced anxiety and alcohol-induced defcits in neurogenesis is less documented. Using the Drinking-In-the-Dark (DID) paradigm to model chronic long-term (12 weeks) binge-like voluntary alcohol consumption in mice, we show that the selective partial activation of 5-HT1A receptors by tandospirone (3 mg/kg) prevents alcohol withdrawal-induced anxiety in a battery of behavioral tests (marble burying, elevated-plus-maze, open-feld), which is accompanied by a robust decrease in binge-like ethanol intake (1 and 3 mg/kg). Furthermore, using triple immunolabelling of proliferation and neuronal diferentiation markers, we show that long-term DID elicits profound defcits in neurogenesis and neuronal fate specifcation in the dorsal hippocampus that are entirely reversed by a 2-week chronic treatment with the 5-HT1A partial agonist tandospirone (3 mg/kg/day). Together, our results confrm previous observations that 5-HT1A receptors play a pivotal role in alcohol drinking behavior and the associated emotional and neurogenic impairments, and suggest that 5-HT1A partial agonists represent a promising treatment strategy for alcohol abuse.
    [Show full text]
  • Alcohol Dependence and Withdrawal Impair Serotonergic Regulation Of
    Research Articles: Cellular/Molecular Alcohol dependence and withdrawal impair serotonergic regulation of GABA transmission in the rat central nucleus of the amygdala https://doi.org/10.1523/JNEUROSCI.0733-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.0733-20.2020 Received: 30 March 2020 Revised: 8 July 2020 Accepted: 14 July 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Alcohol dependence and withdrawal impair serotonergic regulation of GABA 2 transmission in the rat central nucleus of the amygdala 3 Abbreviated title: Alcohol dependence impairs CeA regulation by 5-HT 4 Sophia Khom, Sarah A. Wolfe, Reesha R. Patel, Dean Kirson, David M. Hedges, Florence P. 5 Varodayan, Michal Bajo, and Marisa Roberto$ 6 The Scripps Research Institute, Department of Molecular Medicine, 10550 N. Torrey Pines 7 Road, La Jolla CA 92307 8 $To whom correspondence should be addressed: 9 Dr. Marisa Roberto 10 Department of Molecular Medicine 11 The Scripps Research Institute 12 10550 N. Torrey Pines Road, La Jolla, CA 92037 13 Tel: (858) 784-7262 Fax: (858) 784-7405 14 Email: [email protected] 15 16 Number of pages: 30 17 Number of figures: 7 18 Number of tables: 2 19 Number of words (Abstract): 250 20 Number of words (Introduction): 650 21 Number of words (Discussion): 1500 22 23 The authors declare no conflict of interest.
    [Show full text]
  • Phd Thesis Project: Pharmacological and Toxicological Investigations of New Psychoactive Substances, Supervised by Prof
    PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS OF NEW PSYCHOACTIVE SUBSTANCES Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Dino Lüthi aus Rüderswil, Bern Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung-Nicht kommerziell 4.0 International Lizenz (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.de). Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Stephan Krähenbühl, Prof. Matthias E. Liechti und Prof. Anne Eckert. Basel, den 26.06.2018 Prof. Martin Spiess Dekan der Philosophisch- Naturwissenschaftlichen Fakultät PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS OF NEW PSYCHOACTIVE SUBSTANCES “An adult must make his own decision as to whether or not he should expose himself to a specific drug, be it available by prescription or proscribed by law, by measuring the potential good and bad with his own personal yardstick.” ― Alexander Shulgin, Pihkal: A Chemical Love Story. PREFACE This thesis is split into a pharmacology part and a toxicology part. The pharmacology part consists of investigations on the monoamine transporter and receptor interactions of traditional and newly emerged drugs, mainly stimulants and psychedelics; the toxicology part consists of investigations on mechanisms of hepatocellular toxicity of synthetic cathinones. All research described in this thesis has been published in peer-reviewed journals, and was performed between October 2014 and June 2018 in the Division of Clinical Pharmacology and Toxicology at the Department of Biomedicine of the University Hospital Basel and University of Basel, and partly at the pRED Roche Innovation Center Basel at F.
    [Show full text]